Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib

BACKGROUND: Approximately half of all patients with advanced EGFR-mutant NSCLC will develop acquired resistance to first or second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) with a T790M mutation. In the AURA3 trial, patients with a T790M mutation had a response rate of 71% to osimertini...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Pei N., Roberts, Tara L., Chua, Wei, Becker, Therese M., Caixeiro, Nicole, de Souza, Paul, Gao, Bo, Lee, Chee K., Itchins, Malinda, Westman, Helen, Clarke, Stephen, Blinman, Prunella, Kao, Steven, John, Tom, Leal, Jose L., Bray, Victoria J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107763/
https://www.ncbi.nlm.nih.gov/pubmed/34012779
http://dx.doi.org/10.21037/tlcr-20-1125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107763/
https://www.ncbi.nlm.nih.gov/pubmed/34012779
http://dx.doi.org/10.21037/tlcr-20-1125

Ejemplares similares